Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro (NVRO) and NuVasive (NUVA).
Nevro (NVRO)
Morgan Stanley analyst David Lewis maintained a Sell rating on Nevro today and set a price target of $38. The company’s shares opened today at $37.92, close to its 52-week low of $34.75.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 10.9% and a 65.3% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Nevro is a Hold with an average price target of $53.11.
See today’s analyst top recommended stocks >>
NuVasive (NUVA)
In a report released today, Jonathan Demchick from Morgan Stanley maintained a Hold rating on NuVasive, with a price target of $57. The company’s shares opened today at $48.87, close to its 52-week low of $44.62.
According to TipRanks.com, Demchick is a 3-star analyst with an average return of 7.4% and a 33.3% success rate. Demchick covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Avanos Medical Inc, and Globus Medical.
Currently, the analyst consensus on NuVasive is a Strong Buy with an average price target of $70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
